Vasomera phase 1 clinical trial successfully completed

The drug could treat people with cardiopulmonary disease.

A potential cardiopulmonary disease drug Vasomera has successfully undergone a phase 1 clinical trial, according to manufacturer PhaseBio Pharmaceuticals.

Researchers conducted a randomised double-blind study in order to determine whether subcutaneous doses of the drug were both safe and effective.

Analysts compared pharmacokinetic (PK)/pharmacodynamic (PD) response in 40 patients taking Vasomera or a placebo in order to evaluate whether it would improve symptoms.

Findings provided evidence to show that the selective receptor could appropriately stimulate VPAC1 and VPAC2 proteins in order to target conditions like pulmonary arterial hypertension.

These G-protein coupled receptors are involved in numerous biological functions, including vasodilation, water flux in the lungs and hormone release.

Chief executive at Phase Bio Dr Chris Prior said that the medicine "not only treats the symptoms but potentially alters the underlying pathophysiology of cardiopulmonary diseases".

There were no indications of serious side-effects, and the investigators will not go on to conduct a second phase 1 trial in order to study effects of IV-infused Vasomera.